Symposium

May 3 | 6:30-9:00 PM in Crystal Ballroom

Sponsor: Grifols

Title: Case studies in VWD and Hemophilia A: The key questions

Summary: In a case-based, interactive format, this CME-accredited symposium will explore key questions in the diagnosis and management of von Willebrand disease (VWD) and hemophilia A and B. Faculty members will sit on two panels which will consider cases highlighting controversies, areas of uncertainty, and recent developments in—and ongoing clinical investigation related to—factor replacement therapy for VWD and hemophilia. During the cases, the audience will be polled at different branch-points (the key questions), and will use an audience response system (ARS) to answer them. The panelists will then call on data slides to comment on the audiences' response via the ARS. Topics to be addressed in the cases will include the following: 1) safety of plasma-derived clotting factor concentrates for treatment of von Willebrand disease (VWD), hemophilia A, and hemophilia B; 2) avoidance of inhibitor development; 3) immune tolerance induction (ITI).

PROGRAM:

6:30 – 7:30 pm Registration and dinner

7:30 – 9:00 pm Scientific program

Additional Information and Pre-Registration: http://www.thrombo.net/keyquestions/

May 4 | 12:45-2:00 PM in Grand Ballroom A

Sponsor: Biogen Idec Hemophilia

Title: Genomics in Hemophilia: Applications to Diagnosis and Patient Care

Chair: Barbara Konkle, MD
Director, Translational Research, Puget Sound Blood Center
Professor of Medicine, University of Washington School of Medicine, Seattle, WA

Co-Chairperson: Glenn Pierce, MD, PhD, Senior Vice President, Global Medical Affairs, Biogen Idec, Weston, MA

Faculty:
Neil Josephson, MD
Associate Professor, Division of Hematology
Puget Sound Blood Center and the University of Washington, Seattle, WA

Shannon Meeks, MD
Assistant Professor of Pediatrics
Emory University/Children’s Healthcare of Atlanta, Atlanta, GA

Summary: This session will focus on how advances in genomics can impact both the diagnosis of hemophilia and the care of these patients. Advances in gene sequencing technology and mutational analyses will be discussed as well as how these newer technologies may be used to advance the understanding of disease pathophysiology, and to predict or prevent complications of the disease, such as inhibitors. Overall, this program will highlight how a better understanding of the relationship between genotype and phenotype could lead to new approaches and improved outcomes for hemophilia patients.

PROGRAM:

Using Gene Sequencing Technology to Diagnose Diseases and Guide Treatment

Neil Josephson, MD
Associate Professor, Division of Hematology
Puget Sound Blood Center and the University of Washington, Seattle, WA

Mutation Analysis and Inhibitor Risk in Hemophilia A

Shannon Meeks, MD
Assistant Professor of Pediatrics
Emory University/Children's Healthcare of Atlanta, Atlanta, GA

Panel discussion

Facilitated by Co-Chairpersons
Lunch will be served.

Pre-Registration is not required.

May 4 | 12:45-2:00 PM in Columbus G-L

Sponsor: Boehringer Ingelheim

Title: The Pharmacology and Clinical Use of Pradaxa® (dabigatran etexilate mesylate) capsules

Summary: Boehringer Ingelheim Pharmaceuticals, Inc. presents its satellite symposium, "The Pharmacology and Clinical Use of Pradaxa® (dabigatran etexilate mesylate) capsules". During this presentation attendees will learn key safety and efficacy results from a large clinical trial, pharmacologic properties, and dosing and administration recommendations for PRADAXA.

A promotional presentation brought to you by Boehringer Ingelheim Pharmaceuticals, Inc.

This presentation does NOT qualify for Continuing Medical Education (CME) credit.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals only.

Due to state regulations, we are unable to offer the meal to physicians practicing in the states of Massachusetts, Minnesota, or Vermont, or those who are employed by the state of Colorado.

Faculty:

Jack Ansell, MD

Michael S. Bruno Chairman of Medicine,
Department of Medicine
Lenox Hill Hospital
Professor of Medicine
New York University School of Medicine
New York, NY

PROGRAM

12:45 pm – 1:00 pm Lunch Seating

1:00 pm – 2:00 pm Lecture

Pre-Registration is not required.

May 4 | 6:30-9:00 PM in Grand Ballroom A

Sponsor: Octapharma

Title: VWF/VWD: A new paradigm shift in clinical management moving from diagnosis to testing and treatment

Summary: This interactive dinner symposium will feature well known bleeding disorder experts in the field of Hematology presenting on a new paradigm shift in the management of von Willebrand disease. Presentations will move from the structure and function of VWF under physiological flow conditions to the challenges in diagnosis and clinical testing for von Willebrand disease. A clinical management discussion upon accurate diagnosis will highlight the role of pharmacokinetic profiles for VWF/FVIII concentrates. A final review of challenging VWD cases will be presented to provide solutions in the management of the variability found in von Willebrand disease

Chair: Craig M. Kessler, MD
Professor of Medicine Georgetown University
Director, Comprehensive Hemophilia and Thrombophilia Treatment Center, Washington, DC

Co-Chair: Tom Schleiss, MS, RPh.
Director, Medical Affairs, Local Drug Safety Officer,
Octapharma USA, Hoboken, NJ

Program: Section One - VWF Structure and Function: How do we look at VWF function under flow conditions, Adamts13 in von Willebrand Factor (VWF) Concentrates: Is an Intact VWF Triplet Structure Important for VWF Function? Christoph Kannicht, PhD – Molecular Biochemistry, Octapharma, Berlin, Germany

Section Two - VWF Clinical Testing Update; is there a better mousetrap?
Ken D. Friedman, MD
Director of Hemostasis Laboratory, Medical Director
Blood Center of Wisconsin, Milwaukee, WI

Section Three - Pharmacokinetics and the Impact on VWD Management Comparison of PK Properties of two VWF containing concentrates is a prospective, crossover study.
Craig M. Kessler, MD
Professor of Medicine, Georgetown University
Director, Comprehensive Hemophilia and Thrombophilia Treatment Center, Washington, DC

Section Four – VWD Case Studies Presentations for challenging clinical VWD cases: Experience and Outcomes for effective management.
Mark T. Reding, MD
Center for Bleeding and Clotting Disorders, Minneapolis, MN
University of Minnesota Medical Center - Fairview

Section Five - Octapharma Clinical Research Platform Update on current Octapharma US and International clinical studies.
Sigurd Knaub, MD
Vice President, Clinical Research and Development, Octapharma, Lachen, Switzerland

Registration: To RSVP for this dinner program please email your name and professional affiliation to: [email protected]